Department of Clinical Neurosciences, University Hospital and Faculty of Biology and Medicine, Lausanne, Switzerland.
Division of Clinical Pharmacology, University Hospital and Faculty of Biology and Medicine, Lausanne, Switzerland.
Curr Neuropharmacol. 2019;17(5):447-458. doi: 10.2174/1570159X16666180308154646.
Epilepsy is considered the most frequent severe neurological condition but most patients treated with medication become seizure free. The management of treatment, however, is highly empirical, mainly relying on observation. A closed-loop therapy for epilepsy would be very valuable for more efficient treatment regimens. Here we discuss monitoring treatment (therapeutic drug monitoring) and the potential developments in this field, as well as providing a review of potential biomarkers that could be used to monitor the disease activity. Finally, we consider the pharmacogenetic input in epilepsy treatment.
癫痫被认为是最常见的严重神经系统疾病,但大多数接受药物治疗的患者都能停止发作。然而,治疗的管理主要依赖于观察,是高度经验性的。癫痫的闭环治疗将对更有效的治疗方案非常有价值。在这里,我们讨论了治疗监测(治疗药物监测)和该领域的潜在发展,并对可能用于监测疾病活动的潜在生物标志物进行了综述。最后,我们考虑了癫痫治疗中的遗传药理学输入。